Discover how AAV-based gene therapy delivers anti-eosinophil antibodies, offering hope for chronic hypereosinophilia treatment

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

FRIDAY, Jan. 3, 2025 -- For pediatric patients with Crohn disease, early anti-tumor necrosis factor-alpha (anti-TNFα) therapy is beneficial in...

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying...

THURSDAY, Jan. 2, 2025 -- Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes,...

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.

FRIDAY, Jan. 3, 2025 -- AI can outperform human doctors when it comes to identifying ovarian cancer from ultrasound images.A new study published in...

FRIDAY, Jan. 3, 2025 -- AI can outperform human doctors when it comes to identifying ovarian cancer from ultrasound images.A new study published in...

TUESDAY, Jan. 7, 2025 -- For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about...